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Abstract
Background: Anemia is common among peritoneal dialysis (PD) patients, and most patients require erythropoiesis-
stimulating agents (ESA) to maintain their hemoglobin concentrations within current guideline recommendations.
Darbepoetin alfa is an ESA with a 3-fold longer half-life and greater in vivo biological activity than recombinant
human erythropoietin, allowing less frequent dosing that may simplify anemia management in these patients,
providing benefits to patients, care givers and health care providers. Clinical studies have confirmed the efficacy
and safety of darbepoetin alfa administered at extended dosing intervals. However, there are limited data on the
management of anemia with ESAs in PD patients in routine clinical practice. The aim of this multicenter
observational study in European and Australian dialysis patients was to evaluate darbepoetin alfa administered
once every 2 weeks (Q2W) in routine clinical practice for 12 months.
Methods: PD patients ≥18 years old and converting to treatment with darbepoetin alfa Q2W were eligible for
enrollment regardless of previous or current ESA use. Patients enrolled in the study were treated according to
local usual clinical practice. Data were collected up to 6 months prior to and 12 months after conversion to
darbepoetin alfa Q2W. The primary endpoint was hemoglobin concentration 12 months after conversion
to darbepoetin alfa Q2W.
Results: Of the 741 eligible PD patients (mean age, 61 years; male, 57%), 640 (86%) completed the study. Mean
hemoglobin concentration (g/dL) was 11.69 (95% CI, 11.53-11.86) 6 months before the conversion, 12.25 (95% CI,
12.13-12.38) at conversion, and 11.88 (95% CI, 11.74-12.02) 12 months after conversion to darbepoetin alfa Q2W.
The weekly equivalent ESA dose (μg/wk) was a geometric mean of 25.24 (95% CI, 23.46-27.15) 6 months before
conversion, 20.90 (95% CI, 19.13-22.83) immediately before conversion, 18.89 (95% CI, 18.13-19.68) at conversion
and 19.04 (95% CI, 17.69-20.49) 12 months after conversion. Twelve months after conversion, 70% of patients were
receiving darbepoetin alfa Q2W and 73% had hemoglobin concentrations >11.0 g/dL.
Conclusion: In this large observational study, PD patients were able to maintain mean hemoglobin concentrations
>11.0 g/dL after conversion to extended dosing of darbepoetin alfa Q2W, with no mean dose increase.
Background
Anemia is a frequent and significant complication of
chronic kidney disease (CKD) [1-3]. Current guidelines
recommend the use of erythropoiesis-stimulating agents
(ESAs) for the treatment of anemia of CKD [4-6]. Ane-
mia management with ESAs has been associated with a
reduction in clinical complications due to anemia, and
may improve quality of life [5,7,8].
Peritoneal dialysis (PD) accounts for around 18% of
renal replacement therapy in Europe, although figures
differ substantially between countries [9,10]. Anemia is
common among PD patients, and most require ESAs in
order to maintain hemoglobin concentrations within
guideline recommendations [4,5,11].
ESAs stimulate erythropoiesis through the same
mechanism as erythropoietin, the endogenous glycopro-
tein hormone [3,12]. Darbepoetin alfa (Aranesp
®,
Amgen Inc, Thousand Oaks, CA) has an increased sialic
acid-containing carbohydrate content, resulting in an
approximately 3-fold longer half-life and greater in vivo
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tin (rHuEPO), consequently darbepoetin alfa can be
administered at extended dosing intervals, such as up to
once every 2 weeks (Q2W) for dialysis subjects or once
a month for non-dialysis subjects (13-15).
Clinical trials have confirmed the efficacy and safety of
darbepoetin alfa Q2W in the management of anemia in
patients receiving dialysis, including those on PD
[13-16]. However, there are few data on the actual man-
agement of anemia with ESAs in PD patients in routine
clinical practice. To contribute towards establishing
more data on the use of a Q2W extended dosing regi-
men in this setting, ALTERNATE (A Long-term Non-
interventional Study to Evaluate the Effectiveness of
Aranesp
® in Dialysis Patients When Administered Once
Every Two Weeks) was undertaken. This long-term
observational study followed both hemodialysis and PD
patients treated with darbepoetin alfa Q2W. In this
report, we describe the PD subgroup.
Methods
This was an observational, multi-national study carried
out at 344 centers in Europe and Australia. Patients
≥18 years of age, undergoing routine dialysis (hemodia-
lysis or PD) and initiating treatment with darbepoetin
alfa Q2W were eligible for inclusion. All eligible patients
were enrolled, and enrollment continued sequentially
until the target number of patients was reached. The
final patient completed the study in September 2008.
Patients were excluded if they had received darbepoetin
alfa in an interventional study within 6 months of con-
verting to darbepoetin alfa Q2W, were receiving other
investigational agents, or had clinical evidence of current
malignancy with the exception of basal cell or squamous
cell carcinoma of the skin and cervical intraepithelial
neoplasia.
Data were abstracted from patient charts for up to
6 months prior to and 12 months after conversion to dar-
bepoetin alfa Q2W. Data were abstracted retrospectively
for the 6 months prior to conversion, and retrospectively
and prospectively for the 12 months after conversion,
depending on the date of enrolment in the study. As this
was an observational study, there were no pre-specified
anemia management guidelines or monitoring, and
patients were treated according to the routine clinical
practice in the respective treatment center. Where
required by local law, the study protocol and informed
consent materials were approved by the local Indepen-
dent Ethics Committee, and the patients provided written
informed consent prior to study entry.
Statistical analysis
For the overall study, a sample size of approximately
6000 patients was calculated as the number of patients
needed for the results to have adequate precision for
pre-specified patient subgroups with only 5% of the
total sample (n = 312). The PD subset accounted for
5.1% of the total study population with over 700
enrolled patients.
In the overall study, the primary endpoint was the
hemoglobin concentration 12 months after conversion
to darbepoetin alfa Q2W. Secondary endpoints included
the proportion of patients within European Best Practice
Guidelines treatment targets for hemoglobin (>11 g/dL)
[5], ESA utilization and iron usage, hospitalization and
darbepoetin alfa-related adverse drug reactions (ADRs)
during the 12-month post-conversion period.
Pre-specified analyses were carried out for the PD
subgroup. Continuous variables are described using
mean, standard deviation (SD), 95% 2-sided confidence
intervals (CIs), median, and quartile ranges (Q1, Q3).
Categorical variables are summarized as the number and
percentage of patients.
Analysis of monthly hemoglobin was based on the
value closest to the date of the scheduled time point (eg,
month 1, 2, 3) within a ± 2-week window, with the
exception of the Q2W conversion time point which
included values up to 8 weeks before conversion to
ensure the maximum number of patients for evaluation.
Intrapatient variability was calculated for each patient as
the standard deviation of all monthly hemoglobin results
for the period.
ESA doses were expressed as geometric means (log
transformation of the data) due to the non-normal dis-
tribution of the data. Epoetin doses were converted
from IU to μg using European (200:1) or Australian
(200:1 SC or 240:1 IV) product label guidelines. The
weekly equivalent ESA dose was calculated for indivi-
dual patients for each month using all available dosing
data within that month.
Analyses of endpoints included all eligible patients
enrolled in the study and converted to darbepoetin alfa
Q 2 W( f u l la n a l y s i ss e t[ F A S ] )a so b s e r v e d( n oi m p u t a -
tion for missing values), regardless of subsequent change
in regimen (dose, frequency, or ESA). To assess the
effect of patients’ withdrawal or missing data on hemo-
globin concentration, a FAS last observation carried for-
ward (LOCF) analysis was also undertaken for the
primary endpoint. Additional post-hoc analyses were
undertaken to assess hemoglobin and dose levels in
patients treated with darbepoetin alfa only prior to con-
version to darbepoetin alfa Q2W, and whether the
inclusion of ESA-naïve subjects affected the mean dose
and hemoglobin levels. All statistical analyses were per-
formed with SAS/STAT software (version 8.2, SAS Insti-
tute Inc., Cary, NC, USA).
The ALTERNATE database and statistical analyses
were managed by the study sponsor.
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A total of 742 PD patients were enrolled and 741 were
eligible for the study from 172 centers in 14 European
countries (n = 593) and Australia (n = 148). One patient
was ineligible as age was not confirmed as ≥ 18 years.
Six hundred and forty patients completed the study
(86.4%); the main reasons for discontinuation were kid-
ney transplant (n = 39), and death (n = 36) (Table 1).
Patient demographics and characteristics at conversion
are shown in Table 2. Immediately before conversion,
most patients were receiving darbepoetin alfa (76.1%),
and most had a weekly (QW) ESA regimen (78.4%). In
total, 8.9% of patients had not received an ESA in the 6
months prior to conversion to darbepoetin alfa Q2W
(including ESA-naïve patients and patients who stopped
ESA therapy for 6 months or more).
Hemoglobin and ESA dose
The mean hemoglobin concentration 6 months prior to
conversion to darbepoetin Q2W was 11.69 (95% CI,
11.53-11.86) g/dL, trending upwards to 12.25 (95% CI,
12.13-12.38) g/dL at conversion (Figure 1) in the FAS.
At month 12 after conversion, the mean hemoglobin
concentration was 11.88 (95% CI, 11.74-12.02) g/dL
(Figure 1) in the FAS and 11.83 (95% CI, 11.72-11.94) g/
dL in the LOCF analysis.
Most patients (73.0%) achieved a hemoglobin con-
centration >11 g/dL at month 12 (Figure 2), which was
similar to the proportion of patients 6 months prior to
conversion (69.3%) and at conversion (76.2%). The
proportion of patients achieving a hemoglobin concen-
tration >11 and ≤13 g/dL was 52.5% 6 months prior
to conversion, 43.7% at conversion, and 54.0% at
month 12.
Mean intrapatient variability in hemoglobin was
reduced following conversion to darbepoetin alfa Q2W,
from 0.79 g/dL and 0.90 g/dL 6 to 4 months and 1 to
3 months prior to conversion, respectively, to 0.71 g/dL,
0.65 g/dL, 0.70 g/dL, and 0.65 g/dL in the 3-month peri-
ods from 1 to 12 months after conversion.
The calculated weekly dose of ESA decreased from a
geometric mean of 25.24 (95% CI, 23.46-27.15) μg/wk
6 months prior to conversion to 20.90 (95% CI, 19.13-
22.83) μg/wk the day before conversion. At conver-
sion, the calculated first dose of darbepoetin alfa was
a geometric mean of 18.89 (95% CI, 18.13-19.68) μg/
wk, and 19.04 [95% CI, 17.69-20.49] μg/wk at month
12 (Figure 1). Similar results were observed when only
subjects treated with darbepoetin alfa prior to conver-
sion (n = 564) were analyzed, or when ESA-naïve
patients (n = 66) were excluded from the analyses
[data not shown].
ESA dose remained unchanged in 65.7% and 63.8% of
patients in months 1 to 6, and 7 to 12 after conversion,
respectively, compared with 71.7% in the 6 months prior
to conversion to darbepoetin alfa Q2W. ESA dosing fre-
quency remained unchanged in 79.8% and 74.5% of
patients in months 1 to 6, and 7 to 12 after conversion,
respectively, compared with 82.8% in the 6 months prior
to conversion. Of those patients who had changes in
dose and/or frequency, most patients (88%) had 1 or 2
changes. At month 12, 70.0% of patients were receiving
darbepoetin alfa Q2W and 5.5% of patients were receiv-
ing darbepoetin alfa once a month (Table 3).
Laboratory values
C-reactive protein (CRP) and iron levels were stable
over the study (Figure 2). In patients whose hemoglobin
levels were >11 g/dL for at least 60% of the time follow-
ing conversion, median (Q1, Q3) CRP levels were lower
than in patients with these hemoglobin levels for < 60%
of the time (6.0 [2.9, 14.0] vs. 9.0 [3.5, 21.4] mg/L).
Between 43.2% and 46.6% of patients were on iron
therapy in any 3-month period during the study (Figure 2).
Of those patients on iron therapy, about 60% of patients
were receiving oral iron therapy.
Hospitalizations
During the 12 months after conversion to darbepoetin
alfa Q2W, 52.0% of patients were hospitalized with a
mean duration of 18.8 days (median 14.0 days). The pri-
mary reasons for hospitalization included infection
(40.3%), and hyperkalemia/electrolyte disorders (25.7%),
although most reasons for hospitalization were listed as
‘other’ (51.7%) (Figure 3).
Safety
The ADR rate was low during the 12 months after con-
version to darbepoetin alfa Q2W, with no unexpected
events emerging. A total of 6 ADRs were reported in 4
patients (0.5%). These included myalgia (n = 2), hyper-
t e n s i o n( n=1 ) ,i n j e c t i o ns i t ep a i n( n=1 ) ,m u s c u l a r
weakness (n = 1), and rash (n = 1). A total of 36
patients (4.9%) were withdrawn from the study due to
Table 1 Subject disposition
n (%)
Eligible subjects (full analysis set) 741
Subjects who completed study 640 (86.4)
Subjects who discontinued study 101 (13.6)
Kidney transplant 39 (38.6)
a
Death 36 (35.6)
a
No longer treated at clinic 15 (14.9)
a
Consent withdrawn 1 (1.0)
a
Other 10 (9.9)
a
aPercentage of all subjects who discontinued the study.
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darbepoetin alfa by the investigators.
Discussion
Currently, ALTERNATE is the largest observational
study of ESA use in dialysis patients in Europe and
Australia, and includes a relatively large number of PD
patients. The results of this analysis in PD patients indi-
cate that despite reducing the frequency of administra-
tion, patients converted to darbepoetin alfa Q2W had a
mean hemoglobin concentration >11.0 g/dL 12 months
after conversion, without requiring an increase in mean
dose. Moreover, 70% of patients were receiving darbe-
poetin alfa Q2W at month 12, indicating that most PD
patients were successfully maintained on extended dos-
ing frequency.
I no r d e rt or e c r u i tal a r g e ,d i v e r s ep o p u l a t i o n ,o u r
study had few eligibility criteria. This study included
patients who were ESA naïve, and patients who con-
verted from other ESAs and dosing regimens. Indeed,
the characteristics and hemoglobin concentrations at
conversion were similar to the Netherlands Cooperative
Study on the Adequacy of Dialysis, which included 480
PD patients [17]. This suggests that our patient popula-
tion is typical of European PD patients, and the treat-
ment practices observed are representative of the PD
population. Hospitalizations were frequently reported in
our study, which is typical of a dialysis population, and
the types of ADRs related to darbepoetin alfa were con-
sistent with those reported in controlled trials of dialysis
patients receiving darbepoetin alfa [13,14,16]. Our study
reports that hemoglobin concentrations can be main-
tained >11 g/dL without an increase in mean dose after
conversion to extended (Q2W) darbepoetin alfa dosing
in clinical practice. These results are consistent with
randomized controlled trials of extended Q2W dosing
Table 2 Subject demographics and characteristics at
conversion to darbepoetin alfa Q2W
n = 741
Sex, n (%)
Female 318 (42.9)
Male 421 (56.8)
Not recorded 2 (0.3)
Age (years), mean (SD) 61.2 (15.2)
Age (years), n (%)
<65 413 (55.7)
≥65 328 (44.3)
Primary cause of CKD, n (%)
Diabetes mellitus 140 (18.9)
Glomerulonephritis 139 (18.8)
Hypertension 137 (18.5)
Unknown etiology 108 (14.6)
Polycystic kidney/hereditary disease 67 (9.0)
Interstitial nephropathy/obstructive nephropathy 63 (8.5)
Tumors 6 (0.8)
Other 81 (10.9)
Duration of dialysis (years), mean (SD) 3.1 (3.6)
Duration of dialysis (years), n (%)
<2 years 231 (31.2)
2-5 years 429 (57.9)
>5 years 81 (10.9)
History of cardiovascular disease, n (%) 379 (51.1)
History of diabetes, n (%) 210 (28.3)
Type 1 30 (4.0)
Type 2 173 (23.3)
Diabetic, type not recorded 7 (0.9)
Duration of ESA use
a (years), mean (SD) 2.8 (2.0)
Hb concentration at conversion, g/dL, n (%)
≤11 167 (22.5)
>11-13 307 (41.4)
>13 228 (30.8)
Not recorded 39 (5.3)
ESA treatment prior to conversion, n (%)
Darbepoetin alfa 564 (76.1)
Epoetin alfa 19 (2.6)
Epoetin beta 92 (12.4)
ESA naïve
b 66 (8.9)
ESA frequency prior to conversion
c, n (%)
TIW or BIW 20 (3.0)
QW 529 (78.4)
Other 124 (18.4)
Not recorded 2 (0.3)
ESA route prior to conversion
c, n (%)
IV 41 (6.1)
SC 634 (93.9)
Darbepoetin alfa route at conversion, n (%)
IV 24 (3.2)
SC 717 (96.8)
Table 2 Subject demographics and characteristics at con-
version to darbepoetin alfa Q2W (Continued)
Darbepoetin alfa weekly dose at conversion, μg/wk
Geometric mean (95% CI) 18.89 (18.13-19.68)
Iron status, n (%)
Serum ferritin >100 μg/L and either
TSAT >20% or hypochromic red cells <10%
255 (34.4)
Serum ferritin ≤100 μg/L or both
TSAT ≤20% and hypochromic red cells ≥10%
161 (21.7)
Not recorded 325 (43.9)
an = 718;
breceived no ESA in the 6 months prior to conversion;
cpercentages
calculated excluding ESA-naïve patients.
Abbreviations: BIW, twice a week; CI, confidence interval; CKD, chronic kidney
disease; ESA, erythropoiesis-stimulating agent; Hb, hemoglobin; IV,
intravenous; QW, once a week; Q2W, every two weeks; SC, subcutaneous; SD,
standard deviation; TIW, three times a week; TSAT, transferrin saturation.
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PD patients) [5,16,18], and several smaller studies in PD
patients [14,15,19]. Data from a pooled subanalysis of
eight trials also reported that PD patients can be
switched from epoetin alfa or beta to darbepoetin alfa
Q2W regimen without a dose increase and with mainte-
nance of hemoglobin concentrations [20].
Iron stores were within the European guideline targets
in most patients and up to 47% of patients in any
3-month period were prescribed iron supplementation
in this study [5]. Iron deficiency was reported in 39% of
patients with sufficient data to assess iron deficiency at
conversion. This is of concern as iron deficiency can
inhibit the response to ESAs, and regular assessment is
recommended by European guidelines [5,11].
An upwards trend in hemoglobin concentration was
observed prior to conversion to darbepoetin alfa Q2W.
This may provide insight into the reasons for conversion
to an extended dosing regimen, with physicians less
likely to change an existing treatment regimen in
patients with well controlled hemoglobin, than in
patients who have rising hemoglobin. In addition, hemo-
globin was not stable in many patients in the 3 months
prior to conversion, as reflected in the intrapatient var-
iation, which may have influenced the decision to
switch. The data also indicate a reduction in dose at
conversion, which could suggest that these patients do
not receive the equivalent dosage when converted to an
extended dosing regimen, resulting in a lower hemoglo-
bin after conversion.
Extended dosing may be advantageous in the manage-
ment of anemia in PD patients as it reduces the fre-
quency of ESA administration and may enable
alignment of ESA administration with routine clinic vis-
its, especially since PD patients as a group are not seen
as often by health care providers as hemodialysis
patients [15]. This could reduce both the number of vis-
its and injections required by a patient each month, and
decrease the potential for injection site pain, which may
increase patient satisfaction and improve adherence to
treatment [21-23]. ESA management is also labor inten-
sive and time consuming for health care providers,
requiring frequent hemoglobin monitoring to ensure
that guideline targets are maintained, dose changes for
hemoglobin variation above guideline ranges, and
depending on the ESA half-life, administration up to
three times a week to maintain appropriate hemoglobin
concentrations [23]. Thus, extended dosing may simplify
anemia management for patients, care givers, and health
care providers. Our study indicates that PD patients can
be successfully converted to an extended dosing regi-
men, with 70% of patients receiving darbepoetin alfa
Q2W at month 12.
There are a number of potential limitations to this
study. As this was an observational study, there were no
anemia management guidelines or monitoring, therefore
there may have been differences in hemoglobin targets
and reimbursement for the management of renal anemia
in individual centers and countries. Additionally, there
was no control group or randomization, which limits the
statistical assessment of the data. There may have been
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Figure 1 (A) Mean hemoglobin (g/dL) and calculated geometric
mean weekly erythropoiesis-stimulating agent dose (μg/wk; ±
95% CI) by month in the FAS; (B) Weekly dose day prior to
conversion and first dose of darbepoetin alfa. The mean
hemoglobin concentration 6 months prior to conversion to
darbepoetin Q2W was 11.69 (95% CI, 11.53-11.86) g/dL, trending
upwards to 12.25 (95% CI, 12.13-12.38) g/dL at conversion. At
month 12 after conversion, the mean hemoglobin concentration
was 11.88 (95% CI, 11.74-12.02) g/dL. The calculated weekly dose of
ESA decreased from a geometric mean of 25.24 (95% CI, 23.46-
27.15) μg/wk 6 months prior to conversion to 20.90 (95% CI, 19.13-
22.83) μg/wk the day before conversion (Figure 1B). At conversion,
the calculated first dose of darbepoetin alfa was a geometric mean
of 18.89 (95% CI, 18.13-19.68) μg/wk (Figure 1B), and 19.04 [95% CI,
17.69-20.49] μg/wk at month 12.
aHemoglobin each month was
defined as the single closest value in a ± 2 week analysis window;
at conversion, it was the single closest value in a -8 week analysis
window;
bWeekly dose was the total dose received each month (30
days) converted to a weekly equivalent;
cNo imputation for missing
values; Day -1 was the dose of the regimen the day before
conversion (converted to a weekly equivalent); Day +1 (conversion)
was the first dose of darbepoetin alfa Q2W (converted to a weekly
equivalent) Abbreviations: wk, week; CI, confidence interval; C, at
conversion to darbepoetin alfa every 2 weeks; Hb, hemoglobin FAS,
full analysis set; Q2W, every 2 weeks; darbepoetin alfa every 2
weeks; ESA, erythropoietin stimulating agent; FAS, full analysis set;
Hb, hemoglobin.
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Figure 2 Proportion of patients with hemoglobin concentration in various categories, C-reactive protein (CRP) levels, iron stores and
usage before and after conversion to darbepoetin alfa Q2W. Most patients (73.0%) achieved a hemoglobin concentration >11 g/dL at
month 12, which was similar to the proportion of patients 6 months prior to conversion (69.3%) and at conversion (76.2%). The proportion of
patients achieving a hemoglobin concentration >11 and ≤13 g/dL was 52.5% 6 months prior to conversion, 43.7% at conversion, and 54.0% at
month 12. CRP and iron levels were stable over the study. Between 43.2% and 46.6% of patients were on iron therapy in any 3-month period
during the study. Of those patients on iron therapy, about 60% of patients were receiving oral iron therapy. Abbreviations: C, at conversion to
darbepoetin alfa every 2 weeks; CRP, C-reactive protein; PO, oral; IV, intravenous; Q1-Q3, quartile ranges; TSAT, transferrin saturation.
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the eligibility criteria was aimed at recruiting a wide,
diverse population, and the study protocol required
patient enrollment to be sequential, therefore centers
could not select specific patients. As noted above, the
results of this study indicate that the decision to convert
to darbepoetin alfa Q2W may have been biased toward
patients with increasing hemoglobin prior to conversion.
This may reflect the underlying reasons for conversion to
an extended dosing regimen, rather than an inherent
bias. ESA-naive patients were also included in the analy-
sis, but post-hoc analysis indicated that they did not
impact the results. As observational studies may be lim-
ited by missing data points, we included a sensitivity ana-
l y s i si nw h i c ht h ed a t aw e r ea n a l y z e db ya p p l y i n gL O C F
imputation to evaluate the effects of missing values and
changes in ESA treatment after conversion to darbepoe-
tin alfa Q2W; results were comparable.
In March 2008, during the ALTERNATE study, the
label changed for darbepoetin alfa in Europe. The recom-
mended hemoglobin target was changed from >11.0 g/dL
(with an individualised upper limit of <14.0 g/dL) to a
target of 10.0-12.0 g/dL for all patients. Therefore the
data for patients achieving the previously recommended
hemoglobin target of >11.0 g/dL are no longer exactly
aligned with current targets, and these results may give
the appearance that patients were not achieving target
ranges.
Conclusions
Results from this observational study with darbepoetin
alfa indicate that PD patients can successfully maintain
hemoglobin concentrations within guideline targets in a
clinical practice setting without an increase in the mean
dosage using a darbepoetin alfa Q2W regimen, and pro-
vides insights into the treatment practices of PD patients
receiving ESAs.
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Figure 3 Primary reasons for hospitalization during 12 months
after conversion to darbepoetin alfa Q2W*. The primary reasons
for hospitalization included infection (40.3%), and hyperkalemia/
electrolyte disorders (25.7%), although most reasons for
hospitalization were listed as ‘other’ (51.7%) *Calculated from the
patients’ who were hospitalized, the percentage who had at least
one hospitalization for each reason. Note that more than one cause
of hospitalization could be recorded for the same patient.
Abbreviations: IHD, ischemic heart disease; CHF, chronic heart
failure; PVD, peripheral vascular disease; Q2W, every 2 weeks.
Table 3 Erythropoiesis-stimulating agent type and
frequency at month 12 for peritoneal dialysis patients
who initiated darbepoetin alfa Q2W treatment
Frequency ESA Type (n = 616)
Darbepoetin alfa
n (%)
Epoetin alfa
n (%)
Epoetin beta
n (%)
Total 594 (96.4%) 13 (2.1%) 9 (1.5%)
TIW/BIW 5 (0.8%) 5 (0.8%) 2 (0.3%)
QW 94 (15.3%) 3 (0.5%) 4 (0.6%)
Q2W 431 (70.0%) ––
QM 34 (5.5%) ––
Other 30 (4.9%) 5 (0.8%) 3 (0.5%)
Abbreviations: BIW, twice a week; QW, once weekly; Q2W, once every other
week; QM, once monthly; TIW, three times a week.
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